March 28th 2023
Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.
Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease
Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.
HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib
Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease
Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
Patient Case 2: HER2+ Breast Cancer With CNS Metastases
Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.
Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer
A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.
HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy
Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer Types
December 15th 2022The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBC
December 10th 2022Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.
Treatment Armamentarium for HER2+ Metastatic Breast Cancer
Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.
Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease
Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.